# Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies

> **NCT02292784** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 98 (actual)

## Conditions studied

- Obstetric Labour, Premature

## Interventions

- **DRUG:** Retosiban
- **DRUG:** Atosiban
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02292784
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-01
- **Primary completion:** 2019-09-02
- **Final completion:** 2019-09-02
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2020-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02292784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02292784, "Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02292784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*